PCM
SRRA

Prelude Capital Management’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Prelude Capital Management’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-47,885
Closed -$2.63M – 2199
2022
Q2 		$2.63M Buy
+47,885
New +$2.51M 0.07% 216

Other funds holding SRRA

HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Prelude Capital Management's SRRA Position: Q3 2022 in Review

Prelude Capital Management sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 47,885 shares — an estimated $2.63M sold.

Prelude Capital Management first reported a position in SRRA in Q2 2022 and held it in 1 quarter. The position peaked at $2.63M in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

  • Prelude Capital Management reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Prelude Capital Management sold 47,885 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $2.63M.
  • Prelude Capital Management first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Prelude Capital Management's Sierra Oncology, Inc. Common Stock position peaked at $2.63M in Q2 2022.
  • 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on Prelude Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.